Subgrouping by gene expression profiles to improve relapse risk prediction in paediatric B-precursor acute

Qingsheng Huang1,2, Jiayong Zhong2,3, Huan Gao2

  • 1School of Mathematics and Statistics, Hanshan Normal University, Chaozhou, China.

Cancer Medicine
|May 14, 2021
PubMed

Insights

Subgrouping B-precursor acute lymphoblastic leukemia (ALL) patients by gene expression improves prediction of minimal residual disease (MRD) and relapse-free survival (RFS). This approach helps manage ALL heterogeneity for better treatment tailoring.

Area of Science:

  • Oncology
  • Genomics
  • Bioinformatics

Background:

  • Relapsed acute lymphoblastic leukemia (ALL) is a major cause of childhood cancer mortality.
  • Current treatment stratification faces challenges due to ALL heterogeneity and subtyping difficulties.

Purpose of the Study:

  • To subgroup B-precursor ALL patients using gene expression profiles.
  • To develop predictive models for minimal residual disease (MRD) and relapse-free survival (RFS) within these subgroups.

Main Methods:

  • Unsupervised subgrouping using non-negative matrix factorization and minimum description length.
  • Logistic and Cox regression with elastic net regularization for predictive modeling.
  • Validation of MRD and RFS prediction models across subgroups.

Main Results:

  • Subgrouping improved MRD prediction accuracy in one subgroup (TCF3-PBX1 subtype), achieving AUC of 0.986 (training) and 1.0 (test).
  • RFS prediction models showed acceptable concordance and identified high-risk patients in three subgroups.
  • Identified subgroup-specific genes crucial for prediction models.

Conclusions:

  • Gene expression-based subgrouping effectively addresses B-precursor ALL heterogeneity.
  • Improved prediction of MRD and RFS can be achieved through tailored subgroup analysis.
  • This strategy enhances personalized treatment approaches for pediatric ALL.

Related Concept Videos